People Living with HIV

Doxycycline Post-exposure Prophylaxis better known as Doxy-PEP is a recently introduced sexually transmitted infection (STI) prevention option. Extending access to Doxy-PEP to more individuals within communities for whom it is recommended merits consideration.

Doxy-PEP: What Do We Know?

April 16, 2025

For 340B-covered entities, core to the challenge of navigating a changing and uncertain policy landscape is the complexity of how multiple variables interact differently with each covered health care entity based on its unique makeup of services, funding, patient population, and payer mix. This toolkit aims to assist 340B covered entities in understanding their current areas of funding stability and where they are vulnerable, and to plan for the future.

Navigating changes to the 340B drug pricing program: a toolkit for HIV-related healthcare entities in California

October 4, 2024

In light of proposed and actual changes in Federal and State policy that have the potential to affect the 340B program, we conducted a rapid response study, exploring the impact to facilities that serve people living with or at risk for HIV. As a companion to the Navigating 340B Toolkit, this Explainer takes a closer look at the answers to these three questions: 1. How does 340B work? 2. What is the relationship between 340B and HIV services? 3. What are the current factors impacting 340B revenue for HIV clinical and service organizations?

Navigating 340B amidst policy changes: an explainer

October 4, 2024

The COVID-19 pandemic has renewed concerns about social and structural factors related to health disparities, including those related to HIV. The Lens tool is a partial response to an urgent need to understand whether elevated risk of COVID-19 disease and mortality among persons living with HIV (PLWH) results from related risk behaviors, a higher burden […]

Lens: HIV Prevalence and Mpox Vulnerabilities – A Data Mapping Tool

December 19, 2023